GlassScriptPhysician profile
Inderpreet Sachar
NPI 1619141561
$673.45
in general payments reported to CMS, 2019-2025
13 companies · $140 in 2025
The $140 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $17.00 · 2021: $14.40 · 2022: $23.46 · 2023: $190 · 2024: $177 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $146.09 | 2022-2024 | |
| Abbvie INC. | $125.00 | 2023 | Vraylar |
| Novo Nordisk INC | $122.08 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $59.20 | 2019-2020 | |
| Ucb, INC. | $37.34 | 2024 | Bimzelx, Cimzia |
| Otsuka America Pharmaceutical, INC. | $35.70 | 2023-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $31.62 | 2023-2025 | Rexulti |
| Portola Pharmaceuticals, LLC | $31.25 | 2019 | |
| Astellas Pharma US INC | $25.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.06 | 2023 | |
| Glaxosmithkline, LLC. | $16.14 | 2023 | Shingrix, Trelegy Ellipta |
| Sun Pharmaceutical Industries INC. | $14.40 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inderpreet Sachar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.